Search Results

By The ASCO Post Staff  / Quick Chats

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on CAR T Cells for Hematologic Malignancies: Where We’re At

By The ASCO Post Staff  / 2018 ASH Annual Meeting & Exposition  / Saturday, December 1, 2018 5:45 PM

ASH 2018: Updated Analysis of JULIET Trial: Tisagenlecleucel in Relapsed or Refractory DLBCL

In an update to the global JULIET clinical trial, the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) led to long-lasting remissions in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The most recent results from the trial were presented by...

By The ASCO Post Staff  / 23rd Congress of EHA  / Tuesday, June 19, 2018 2:59 PM

EHA 2018: Tisagenlecleucel Demonstrates More Than 1-Year Durability of Response in Adults With Relapsed or Refractory DLBCL

Fourteen-month results from the JULIET clinical trial showed ongoing durable responses are achievable with tisagenlecleucel (Kymriah) when administered to adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This updated analysis was presented by Borchmann et al at ...

By The ASCO Post Staff  / Wednesday, May 2, 2018 5:31 PM

FDA Expands Tisagenlecleucel Approval to Include Relapsed or Refractory Large B-Cell Lymphoma

On May 1, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel (Kymriah) suspension for intravenous infusion for the treatment of adult patients with relapsed or refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and...